Myfembree (Relugolix/Estradiol/Norethindrone aceta

Ryeqo is indicated for treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. One tablet of Ryeqo must be taken once daily, at about the same time with or without food. Tablets should be taken with some liquid as needed. Ryeqo can be taken without interruption. Discontinuation should be considered when the patient enters menopause, as uterine fibroids are known to regress when menopause begins.

Ingredients

Lactose monohydrate Mannitol (E421) Sodium starch glycolate Hydroxypropyl cellulose (E463) Magnesium stearate (E572) Hypromellose type 2910 (E464) Titanium dioxide (E171) Triacetin (E1518) Iron oxide yellow (E172)

Cautions

In patients with risk factors for osteoporosis or bone loss, a dual X-ray absorptiometry (DXA) is recommended prior to starting Ryeqo treatment.

Side Effects

Psychiatric disorders - Irritability Vascular disorders - Hot flush Gastrointestinal disorders - Dyspepsia Skin and subcutaneous tissue disorders - Alopecia , Hyperhidrosis , Night sweats Reproductive system and breast disorders - Uterine bleeding , Breast cyst, Libido decreased